Introduction {#Sec1}
============

The renin-angiotensin system (RAS) represents one of the most important therapeutic targets for the treatment of cardiovascular diseases. During the last 20 years, angiotensin-converting enzyme 2 (ACE2) has been shown to contribute to the maintenance of normal cardiovascular function. Its major role includes hydrolysis of angiotensin (Ang)-I and Ang-II to vasodilatory peptides Ang-(1--9) and Ang-(1--7), respectively (Donoghue et al. [@CR8]; Vickers et al. [@CR36]; Xu et al. [@CR42]). Ang-(1--9) and Ang-(1--7) acting putatively through Ang-II type 2 receptor (AT~2~R) and Mas1 receptor (Mas1R) (Filipeanu and Lazartigues [@CR14]; Karnik et al. [@CR19]; Mendoza-Torres et al. [@CR25]) attenuate the proliferative and contractile effects of AT~1~R activation by Ang-II and ultimately opposing the development of hypertension (Xu et al. [@CR41], [@CR42]). Recently, ACE2 was also identified as a "receptor" for the SARS-CoV-2 virus responsible for the COVID-19 pandemic. ACE2 contains a single HEXXH zinc-binding domain which is homologous to one of the active sites of ACE and shares 40% overall identity to ACE but its enzymatic activity is not sensitive to typical ACE inhibitors (Donoghue et al. [@CR8]; Vickers et al. [@CR36]).

Overexpression of ACE2 has been shown to prevent the development of hypertension (Feng et al. [@CR11], [@CR12]), whereas its downregulation leads to chronic increase in blood pressure levels (Deshotels et al. [@CR7]; Xu et al. [@CR42]). ACE2 can also be shed and enter the circulation under action of metalloproteases such as ADAM17 (de Queiroz et al. [@CR6]; Xu et al. [@CR41]). However, hydrolysis of Ang-II is mediated in large part by cellular ACE2 (Mukerjee et al. [@CR26]; Pedersen et al. [@CR30]) and requires the carboxypeptidase to be present on the cell surface (Deshotels et al. [@CR7]). Our group originally demonstrated that Ang-II induces ACE2 internalization and degradation into lysosomes through an Ang-II type 1 receptor (AT~1~R)-dependent mechanism and this process leads to a decrease in the expression levels and activity of the enzyme (Deshotels et al. [@CR7]). However, the molecular mechanisms controlling ACE2 trafficking to lysosomes remain unclear.

Intracellular protein trafficking is a highly regulated process controlled by interactions with specific accessory proteins (also named molecular chaperones) (Ciruela et al. [@CR4]; Filipeanu [@CR13]; Rodemer and Haucke [@CR32]). Indeed, AT~1~R-associated protein (ATRAP) was shown to interact with AT~1~R (Lopez-Ilasaca et al. [@CR22]) and microtubule-associated tumor suppressor gene (MTUS1)/ AT~2~R interacting protein (ATIP) with AT~2~R (Bozgeyik et al. [@CR2]). Interestingly, at least one MTUS1/ATIP isoform, ATIP3a was reported to be co-localized with microtubules, which form the cell cytoskeleton (Bozgeyik et al. [@CR2]). No such proteins are yet known for ACE and ACE2, but because both enzymes are internalized from plasma membrane to endosomes (Deshotels et al. [@CR7]; Lucero et al. [@CR23]), the availability of such accessory proteins can be predicted. Identification of these binding partners may offer additional pharmacological and therapeutic tool to target RAS activity and SARS-CoV-2 infection. Therefore, the aim of the present work was to identify and characterize accessory proteins involved in ACE2 internalization.

Materials and Methods {#Sec2}
=====================

Materials {#Sec3}
---------

Plasmids used in this study were obtained as follows: Human GFP-tagged ACE2 was from Origene, human fascin-1 (FusionRed-Fascin-C-10) was a gift from Michael Davidson (Addgene plasmid \# 56117), human HA-tagged AT~1~R was a gift from Dr. Guangyu Wu (Medical College of Georgia). Cell culture medium, antibiotics, Lipofectamine 2000, and fetal bovine serum (FBS) were from Thermofisher; normal donkey serum was from Sigma-Aldrich; antibodies against ACE2 (sc-390851), GFP (sc-9996), β-actin (sc-8432) and fascin-1 (sc-46675), as well as lentiviral shRNA particles against fascin-1 (sc-35359-V) were obtained from Santa Cruz Biotechnology. The α-tubulin antibody (T6199) and deoxycorticosterone acetate (DOCA) were from Sigma-Aldrich. HEK293T cells (ATCC CRL-3216) were used in this study between passage number 4 and 27.

Cell Culture and Transfection {#Sec4}
-----------------------------

HEK293T were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 10 units/mL penicillin, and 100 μg/mL streptomycin. The cells were plated in 6-well plates and transfected at \~ 80% confluency with 0.5 µg of ACE2-GFP, 0.5 µg AT~1~R-HA, and/or 0.5 µg fascin-1 using Lipofectamine 2000 reagent in Dulbecco's modified Eagle's medium with no antibiotics and no fetal bovine serum. After 6 h, the cells were cultured in full medium for 48 h, serum starved for another 24 h before performing the experiments.

Confocal Microscopy {#Sec5}
-------------------

For confocal microscopy, HEK293T cells were grown on coverslips pre-coated with poly-[l]{.smallcaps}-lysine in 6-well plates and transfected. The cells were fixed with a 4% paraformaldehyde/4% sucrose mixture in PBS for 15 min and stained with 4, 6-diamidino-2-phenylindole for 5 min. For plasma membrane staining, cells were incubated with WGA (Thermofisher) prior to fixation. The cells were permeabilized in PBS and blocked with normal donkey serum. The cells were then incubated with antibodies dilution of 1:1000 overnight at 4 °C. After washing with PBS (3 × 5 min), the cells were incubated with Alexa Fluor 594-labeled secondary antibody (1:1000 dilution) for 1 h at room temperature. Fluorescent images of fixed samples were captured using a Nikon Ti-E-PFS inverted spinning-disk confocal microscope equipped with a 60 × 1.4 NA Plan Apo Lambda objective.

Western Blotting {#Sec6}
----------------

Transfected cells were collected in loading buffer (1X Laemmle buffer) then samples were separated by 10% sodium dodecyl sulfate--polyacrylamide gel electrophoresis, followed by transfer onto polyvinylidene fluoride (PVDF) membranes. The membranes were then exposed to specific primary and secondary antibodies then protein levels were visualized using LiCor digital blot scanner (LiCor bioscience) and quantified using LiCor software.

For mouse samples, hypothalamic proteins (30--50 μg) were processed for Western blotting as previously described,(Xia et al. [@CR39]) using a mouse anti-fascin monoclonal primary antibody (Cell Signal Technology 54545S, 1:1000) and a goat anti-mouse IgG, HRP conjugate (Sigma-Aldrich A9917, 1:5000) as secondary antibody. α-tubulin (Sigma-Aldrich T6199, 1:10,000) was used as a loading control.

Co-immunoprecipitation {#Sec7}
----------------------

The cells were lysed in a co-immunoprecipitation buffer (50 mM Tris--HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and Complete Mini protease inhibitor cocktail) two days after transfection. The samples were centrifuged (13,200 rpm) and the supernatant was collected and subsequently incubated with 50 μL of protein A/G Sepharose at 4 °C overnight, followed by incubation with anti-GFP antibodies (1 μg/mg protein) at 4 °C for 4 h. The protein complexes were recovered with 50 μL protein A/G Sepharose and further processed by Western blotting.

Determination of ACE2 Activity {#Sec8}
------------------------------

Transfected HEK293T cells were extracted in ACE2 reaction buffer (0.5% Triton X-100 in ACE2 reaction buffer containing 1 M NaCl, 0.5 mM ZnCl~2~, 75 mM TrisHCl and 100 μM Mca-YVADAPK (Dnp, from Anaspec Inc, Freemont, CA) and were sonicated 4 × 5 s and centrifuged at 20,817×*g* at 4 °C for 10 min. The supernatant was recovered, and the protein concentration was determined by Bradford method. Each reaction used 10 μg of cell lysates. Fluorescence emission was detected at 405 nm, after excitation at 320 nm in a Biotek Cytation 3 spectrometer, and the slope of fluorescence development was calculated between 10 and 120 min of incubation. Blank values were obtained with extraction buffer only and were subtracted from the hydrolysis rates of the sample extracts. Hydrolysis rates were quantified as fluorescence units per minute per amount of protein and are reported as percentage of the values obtained in control (untreated) cells. The control values in ACE2-transfected cells amounted to 21,545 ± 2721 arbitrary units (a.u.).

Protein Interaction with ACE2 Identification by Liquid Chromatography--Mass Spectrometry Analysis {#Sec9}
-------------------------------------------------------------------------------------------------

The cells were transfected and processed as above, followed by treatment with Ang-II for 4 h. Cellular lysates were obtained as in co-immunoprecipitation experiments and subsequently two-dimensional difference gel electrophoresis labeling and analysis was performed as previously described (Filipeanu [@CR13]). Fluorophore-labeled protein gels were scanned using a Typhoon 9400 Variable Mode Imager (GE Healthcare, Piscataway, NJ) at 100 μm resolution. CyDye (GE Healthcare) difference gel electrophoresis labeling was detected using the following wavelength settings: Cy2, excitation 488 nm, emission 520 nm; Cy3, excitation 532 nm, emission 580 nm; and Cy5, excitation 633 nm, emission 670 nm. Spot detection and quantification were performed using the DeCyder differential analysis software DIA, version 5.0 (GE Healthcare) and individual gels were imported into DeCyder biologic variation analysis for *t* test analysis. Spots of interest were determined to have a difference greater than 50% or a *t*test *p*value of less than 0.05. Gels were then post stained with Sypro Ruby (Bio-Rad), and images were captured again using the Typhoon 9400 Imager (GE Healthcare). Spots of interest were excised and trypsin (Promega, Madison, WI) digested using the automated Spot Handling Workstation (GE Healthcare).

The mass spectrometry (MS) data were acquired using a Thermo LTQ-XL linear ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to an Eksigent nanoLC (Dublin, CA). Peptide samples were loaded onto a Dionex C18 PepMap 100 trap column with dimensions of 300 μm (i.d.) × 5 mm (Dionex, Sunnyvale, CA) and were separated by a reversed-phase C18 PicoFrit emitter with dimensions of 75 μm (i.d.) × 10 cm (bed length) with 15 μm tip size (New Objective, Woburn, MA). Peptides were loaded at 500 nL/min using a mobile phase of 2% acetonitrile and 0.1% formic acid and then eluted using a gradient of 5--40% acetonitrile and 0.1% formic acid over 16 min, with a ramp to 60% acetonitrile and 0.1% formic acid for 10 min, and finally a ramp to 95% acetonitrile and 0.1% formic acid for 10 min. A top five data-dependent scan strategy was used. The MS1 scan range was between m/z 300 and 2000. The top most abundant peptides in this MS1 scan were chosen for MS/MS. The MS/MS parameters were the following: isolation window set to 2 Da, 35% relative collision energy, dynamic exclusion enabled with repeat count set to 1, repeat duration of 30 s, and an exclusion size of 100 with an exclusion duration of 20 s. The MS data were then analyzed by Proteome Discoverer 1.4 (Thermo Fisher Scientific) against the Human SwissProt database (<https://www.uniprot.org/proteomes/>).

Animal Studies {#Sec10}
--------------

C57Bl6/J male mice (10--12 weeks old, *n* = 3/group) were anesthetized with isoflurane (2%) and implanted subcutaneously with a DOCA (1 mg/g body weight) pellet and switched to a 1% NaCl drinking solution, as described previously (Sriramula and Lazartigues [@CR33]). After 3 weeks, mice were euthanized and the hypothalamus was dissected for protein extraction and Western blotting analysis, as mentioned above. All procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Louisiana State University Health Sciences Center (\#3450) Institutional Animal Care and Use Committee.

Statistical Analysis {#Sec11}
--------------------

Each experiment was run in triplicate and repeated at least in three different passages. Data are presented as means ± S.E.M. Statistical analysis was performed using one-way ANOVA, followed by the Tukey post-analysis and *p* \< 0.05 was considered as statistically significant.

Results {#Sec12}
=======

To identify new proteins interacting with ACE2, we performed a proteomic experiment in ACE2-transfected HEK293T cells. From the two--dimensional difference gel electrophoresis, seven spots appeared different between control and Ang-II-treated cells (100 nM, 4 h, Fig. [1](#Fig1){ref-type="fig"}a). However, after trypsin digestion and mass spectrometry analysis, we found that all these spots identified a single protein, namely fascin-1 (Fig. [1](#Fig1){ref-type="fig"}b). The different spots represent electronegative shifts caused by isoelectric focusing point changes due to post-translational modifications and most likely represent phosphorylation differences. Known phosphorylation sites for Fascin-1 include Serine-38, Serine-39, Serine-127, Serine-234, Threonine-239, and Threonie-403.Fig. 1**a** Representative experiments showing 2-D gels for control (left) and Ang-II (100 nM, 4 h, right)-treated GFP-ACE2-transfected HEK293T cells. The indicated five spots were excised, picked, and digested, and identified by LTQ electrospray mass spectroscopy as described in Material and Methods. Similar results were obtained in two additional experiments. **b** Identification of fascin-1 as an accessory protein of ACE2. Full sequence of human fascin-1 (Q16658). Underlined peptides are those that were obtained by trypsinization and subsequent mass spectrometry

To confirm that indeed ACE2 interacts with fascin-1, we first performed co-localization experiments by confocal microscopy. In HEK293T cells co-transfected with GFP-tagged ACE2, HA-AT~1~R, FusionRed-Fascin-1, we found that in control conditions ACE2 and fascin-1 are co-localized at the plasma membrane level (Fig. [2](#Fig2){ref-type="fig"}a, top panel). However, after treatment with Ang-II (100 nM, 4 h), both proteins displayed perinuclear localization, but very little, if any, co-localization. No co-localization between ACE2 and fascin-1 was observed in absence of AT~1~R transfection (data not shown). Co-immunoprecipitation experiments demonstrated interactions between ACE2 and fascin-1 (Fig. [2](#Fig2){ref-type="fig"}b). Ang-II treatment (100 nM, 4 h) did not have an effect on ACE2/fascin-1 interactions when immunoprecipitation was performed in cells without overexpression of fascin-1. However, in fascin-1-overexpressing cells, Ang-II treatment appears to decrease ACE2/fascin-1 interactions (Fig. [2](#Fig2){ref-type="fig"}b, last two lanes).Fig. 2**a** Co-localization of ACE2 and fascin-1 at subcellular level. HEK293T cells were co-transfected with GFP-tagged ACE2 and FusionRed-Fascin-C-10, processed as described in Material and Methods and examined by confocal microscopy. The far-right panels represent × 3 magnification of the boxes shown the merged column. The pictures shown are representative from three independent transfections, each performed in triplicate. **b** Interactions between ACE2 and fascin-1 revealed by co-immunoprecipitation. HEK293T cells were processed as described in Material and Methods, subject to the indicated treatments, lysed and immuno-precipitated with GFP antibody. GFP immuno-precipitates (20 μg/lane) were separated by 10% SDS-Page and the ACE2 levels were revealed by Western blotting. The band corresponding to the molecular weight of fascin-1 (54.3 kDa) is indicated by white arrow. The inputs indicate 1/100 from the initial cell lysates which were not subject to immunoprecipitation. The experiment shown is representative from three independent transfections

Next, we investigated if changes in cellular levels of fascin-1 are modulating ACE2 activity and expression levels. In untransfected HEK293T cells, ACE2 activity was below detection limit (328 ± 645 a.u., *n* = 6). In HEK293T cells transfected only with ACE2 plasmid, ACE2 activity in control conditions amounted to 21,545 ± 2721 a.u., and, in agreement with our previous report (Deshotels et al. [@CR7]), Ang-II treatment (100 nM, 4 h) did not have any effect (21,381 ± 2894 a.u., *n* = 6). However, in cells co-transfected with AT~1~R, Ang-II treatment (100 nM, 4 h) induced a significant reduction of ACE2 activity (22.1 ± 9.2% from the values obtained in the untreated cells which was 20,120.11 ± 6827.12 a.u. n = 12, Fig. [3](#Fig3){ref-type="fig"}a, *p* \< 0.05). Overexpression of fascin-1 did not change basal ACE2 activity (93.3 ± 5.1%, Fig. [3](#Fig3){ref-type="fig"}a), but prevented the effects of Ang-II on this parameter (98.1 ± 6.8%, Fig. [3](#Fig3){ref-type="fig"}a). When we tested the effects of a longer Ang-II treatment (100 nM, 18 h), which we have shown to induce ACE2 degradation in lysosomes (Carvalho-Galvao et al. [@CR3]; Deshotels et al. [@CR7]) in control cells, we found the expected decrease in total cellular levels (Fig. [3](#Fig3){ref-type="fig"}b). However, in cells overexpressing fascin-1, this effect was abolished (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 3**a** The effects of Ang-II on ACE2 activity in cells transfected with GFP-ACE2 (0.5 μg) HA-AT1R (0.5 μg) and co-transfected with control plasmid (pcDNA3.1) or fascin-1 plasmid (0.5 μg each). Ang-II treatment (100 nM) lasted for 4 h and it was performed after starving the cells for 24 h. The data are presented as % from ACE2 activity determined in untreated cell, which was 20,120.11 ± 6827.12 a.u. Mean ± S.E.M. from five independent transfections, each performed in triplicate. \*Indicates statistical significant differences with *p* \< 0.05, using a two-tail Student's *t* test. **b** The effects of Ang-II on total ACE2 cellular levels are prevented by overexpression of fascin-1. Left: Representative blots showing the levels of ACE2, fascin-1, and β-actin in cells transfected with empty plasmid (pcDNA3.1, left) or fascin-1 (right), in the absence or presence of Ang-II (100 nM, 18 h). Right: Quantification of the results obtained in three separate experiments performed in similar manner as in the left. ACE2 levels were quantified and normalized to β-actin and are expressed as percentage from the levels in control cells. *n* = 3, \*indicate *p* \< 0.05 vs. control

To confirm these results, we generated stable HEK293T cells with reduced fascin-1 cellular levels. Using puromycin selection after treatment with fascin-1 shRNA lentivirus, we generated a clone with \~ 90% reduction in total fascin cellular levels (Fig. [4](#Fig4){ref-type="fig"}a). In these cells, we found a major reduction in ACE2 activity in basal conditions (\~ 75% inhibition) and treatment with Ang-II (100 nM, 4 h) did not produce a further inhibitory effect (Fig. [4](#Fig4){ref-type="fig"}b).Fig. 4**a** Downregulation of fascin-1 levels by lentiviral shRNA. Top: Fascin-1 cellular levels in puromycin-selected HEK293T clones treated with GFP-lentivirus (sc-108084, left two lanes) and fascin-1 shRNA lentivirus (sc-35359-V, right two lanes). These clones were selected using puromycin resistance as described in Material and Methods and subjected to Western blotting. Bottom: β-actin cellular levels in the same clones. Similar results were obtained in three independent experiments. **b** Reduced cellular fascin-1 levels diminished ACE2 activity. ACE2 activity was determined in stable HEK293T clones shown in **a**, obtained after treatment with GFP- or fascin-1 shRNA lentivirus in the absence or in presence of Ang-II (100 nM, 4 h). Mean ± S.E.M., from two separate experiments, each performed in triplicate. \*Indicate statistical significant differences with *p* \< 0.05, vs. control cells using a two-tail Student's *t* test: \# indicates statistical significant decrease in ACE2 activity in fascin-1-downregulated cells using one-way ANOVA

To investigate whether these in vitro results can be related to pathological effects observed in vivo, we tested the levels of fascin-1 in brain homogenates from hypertensive mice. Mice undergoing a standard DOCA-salt protocol develop chronic hypertension within days which remains stable for several weeks (Xia et al. [@CR40]). The hypothalamus of these DOCA-salt-treated hypertensive mice was assessed for fascin-1 protein expression. As shown in Fig. [5](#Fig5){ref-type="fig"}, fascin-1 levels were significantly reduced in chronically hypertensive mice.Fig. 5**a** The effects of DOCA-salt-treatment on fascin-1 cellular levels in vivo. Hypothalamus proteins from sham and DOCA-salt-treated mice were analyzed by Western blotting. **b** Quantification of experiments (*n* = 3) shows that hypertension is associated with a reduction in fascin-1 levels. \*Indicates statistical significance (*p* \< 0.05) vs. sham group using a two-tail Student's *t* test. Data are expressed as mean ± S.E.M

Discussion {#Sec13}
==========

ACE2 was discovered in 2000, as a homologue of ACE with which it shares about 40% protein sequence identity in the catalytic domains (Donoghue et al. [@CR8]; Vickers et al. [@CR36]). However, in contrast to ACE, ACE2 hydrolyses Ang-I and Ang-II to produce the vasodilator peptides Ang-(1--9) and Ang-(1--7)(Ocaranza et al. [@CR28]; Xu et al. [@CR42]), which counteracts the adverse effects of an overactive RAS (Feng et al. [@CR11], [@CR12]). In addition, ACE2 is also the plasma membrane receptor for SARS-coronaviruses responsible for severe acute respiratory syndrome and COVID-19, (da Costa et al. [@CR5]; Giannis et al. [@CR16]; Petrosillo et al. [@CR31]). While ACE2 shedding has been demonstrated as a mechanism contributing to the development of hypertension (Carvalho-Galvao et al. [@CR3]; Xia et al. [@CR40]; Xu et al. [@CR41]), much less is known about the regulation of de novo ACE2 synthesis and its intracellular trafficking in normal and pathological conditions. Intracellular trafficking is a strictly regulated process, involving several steps which include interactions with specific proteins designated accessory proteins or molecular chaperones (Ciruela et al. [@CR4]; Filipeanu [@CR13]; Rodemer and Haucke [@CR32]). ACE2-interacting proteins have not been investigated thus far and our group previously demonstrated that Ang-II induces ACE2 internalization and degradation into lysosomes through an AT~1~R-mediated mechanism (Deshotels et al. [@CR7]).

In the present work, we identify fascin-1 as the only protein which in HEK293T cells has differential interactions with ACE2 after 4 h treatment with Ang-II, a time point that coincides with the lysosomal targeting of this enzyme (Deshotels et al. [@CR7]). Fascin belongs to the large family of actin bundling proteins and has three different isoforms, fascin-2 being mostly expressed in retinal cells (Wada et al. [@CR37]), fascin-3 only in testes (Adams [@CR1]; Fagerberg et al. [@CR10]), whereas fascin-1 is expressed ubiquitously but with greater extent in mesenchymal and nervous tissues (Jayo and Parsons [@CR18]). Fascin-1 plays important roles in cell adhesion, migration, and neuronal growth cone morphogenesis and reorganization (Adams [@CR1]; Gallop [@CR15]; Wei et al. [@CR38]). Phosphorylation of fascin-1 by protein kinase C has been shown to abolish its actin bundling activity (Adams [@CR1]; Jayo and Parsons [@CR18]), whereas interactions of fascin-1 with Rac- and Rab35 GTP-ases were suggested to play a role in vesicular trafficking (Fagerberg et al. [@CR10]; Parsons and Adams [@CR29]; Zhang et al. [@CR43]). Fascin-1 is overexpressed in many human cancers and its expression levels positively correlates with aggressive tumors (Jayo and Parsons [@CR18]; Kulasingam and Diamandis [@CR21]; Tan et al. [@CR34]).

However, the present study shows that fascin-1 can also play a role in the regulation of cardiovascular activity, particularly in regulating expression levels and subcellular localization of ACE2. Our results using proteomics, confocal microscopy, co-immunoprecipitation, and enzymatic activity demonstrate that fascin-1 interacts with ACE2. Importantly, when fascin-1 intracellular levels are increased, the effects of Ang-II on ACE2 internalization are greatly reduced (Fig. [3](#Fig3){ref-type="fig"}). In contrast, a decrease in fascin-1 cellular levels leads to a major decline in ACE2 activity (Fig. [4](#Fig4){ref-type="fig"}), strongly suggesting that an optimal expression level of fascin-1 is required for maintaining the compensatory role of this enzyme against an overactive RAS. Even more interesting, we found that in the hypothalamus of DOCA-salt-induced hypertensive mice, a region known for harboring pre-sympathetic neurons involved in autonomic regulation (Mukerjee et al. [@CR26]), the levels of fascin-1 were reduced. Cytoskeletal rearrangements by contractile stimuli in vascular smooth muscle cells have been reported (Ishida et al. [@CR17]), and a decrease in fascin-1 cellular levels was observed in rapid ischemic neuronal response as well as in renal podocytes after mechanical stress (Kliewe et al. [@CR20]; Meller et al. [@CR24]). However, the present work is the first observation that fascin-1 is decreased in chronic neurogenic hypertension. We propose that in normal conditions ACE2 is maintained to the plasma membrane through interactions with fascin-1, but in the presence of enhanced circulating Ang-II, these interactions are attenuated and the enzyme is internalized and degraded, a process that is enhanced in cells with reduced fascin-1 levels (Fig. [6](#Fig6){ref-type="fig"}), in agreement with our previous observations that ACE2 is reduced in this model (Xia et al. [@CR40]).Fig. 6Schematic diagram of the proposed involvement of fascin-1 in the regulation of ACE2 subcellular localization and expression levels. In normal conditions, fascin-1 binds to ACE2 and supports the enzyme localization to the plasma membrane (left). Increase in extracellular Ang-II concentrations leads to interactions between AT~1~R and ACE2 followed by internalization of the complex in endosomes, where it dissociates followed by AT~1~R recycling to the plasma membrane and the enzyme transport to lysosomes (Deshotels et al. [@CR7]). In addition, decreases in fascin-1 cellular levels further contribute to ACE2 degradation (right)

Rearrangement of actin cytoskeleton has been shown to play important roles in intracellular traffic (Gallop [@CR15]) and various proteins have been shown to specifically regulate the transport of receptors like tubulin for AT~1~R and α~2B~-adrenergic receptors (Duvernay et al. [@CR9]; Zhang et al. [@CR44]), filamin A for somatostatin receptor type 2 (Treppiedi et al. [@CR35]), and ERM proteins for tyrosine kinase receptors and viruses (Neisch and Fehon [@CR27]). Our data reveal that beside the previously reported functions of fascin-1 (Adams [@CR1]; Gallop [@CR15]; Jayo and Parsons [@CR18]), this actin bundling protein also mediates the traffic from plasma membrane to endo-lysosomal system. Whether or not this role is limited to ACE2 or fascin-1 may interfere with the traffic of other proteins remains to be determined.

In conclusion, we identified fascin-1 as an ACE2-accessory protein, interacting with the enzyme in an Ang-II-dependent manner. Moreover, fascin-1 expression levels represent an additional mechanism involved in the regulation of ACE2 activity and ultimately in the regulation of autonomic and cardiovascular functions.

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work was supported by NIH R01HL150592-01 Grant (to CMF and EL), COBRE Grant Number P30GM106392 (to EL and JJG), Merit Award (I01 BX004294) from the US Department of Veterans Affairs (to EL), and bridge funds from Howard University (to CMF).

All authors declare that they have no conflicts of interest.
